|
1
|
Yung KW, Yung TT, Chung CY, Tong GT, Liu
Y, Henderson J, Welbeck D and Oseni S: Principles of cancer
staging. Asian Pac J Surg Oncol. 1:1–16. 2015.
|
|
2
|
Zheng YF, Tan LK, Tan BH, Sterling H and
Kane R: Principles of surgical oncology. Asian Pac J Surg Oncol.
1:17–26. 2015.
|
|
3
|
Fukuoka M, Yano S, Giaccone G, Tamura T,
Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S,
Rischin D, et al: Multi-institutional randomized phase II trial of
gefitinib for previously treated patients with advanced
non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol.
21:2237–2246. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen MH, Williams GA, Sridhara R, Chen G
and Pazdur R: FDA drug approval summary: Gefitinib (ZD1839)
(Iressa) tablets. Oncologist. 8:303–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cufer T, Vrdoljak E, Gaafar R, Erensoy I
and Pemberton K: SIGN Study Group: Phase II, open-label, randomized
study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as
second-line therapy in patients with advanced (stage IIIb or IV)
non-small-cell lung cancer. Anticancer Drugs. 17:401–409. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Thatcher N, Chang A, Parikh P, Pereira J
Rodrigues, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH,
Pemberton K, Archer V, et al: Gefitinib plus best supportive care
in previously treated patients with refractory advanced
non-small-cell lung cancer: Results from a randomised,
placebo-controlled, multicentre study (Iressa Survival Evaluation
in Lung Cancer). Lancet. 366:1527–1537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niho S, Ichinose Y, Tamura T, Yamamoto N,
Tsuboi M, Nakagawa K, Shinkai T, Jiang H, Nishiwaki Y and Fukuoka
M: Results of a randomized Phase III study to compare the overall
survival of gefitinib (IRESSA) versus docetaxel in Japanese
patients with non-small-cell lung cancer who failed one or two
chemotherapy regimens. J Clin Oncol. 25:2007.
|
|
8
|
Kim ES, Hirsh V, Mok T, Socinski MA,
Gervais R, Wu YL, Li LY, Watkins CL, Sellers MV, Lowe ES, et al:
Gefitinib versus docetaxel in previously treated non-small-cell
lung cancer (INTEREST): A randomised phase III trial. Lancet.
372:1809–1818. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lee DH, Park K, Kim JH, Lee JS, Shin SW,
Kang JH, Ahn MJ, Ahn JS, Suh C and Kim SW: Randomized phase III
trial of gefitinib versus docetaxel in non-small cell lung cancer
patients who have previously received platinum-based chemotherapy.
Clin Cancer Res. 16:1307–1314. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamil N, Kamil S, Ahmed SP, Ashraf R,
Khurram M and Ali MO: Toxic effects of multiple anticancer drugs on
skin. Pak J Pharm Sci. 23:7–14. 2010.PubMed/NCBI
|
|
11
|
Yang JC, Wu YL, Chan V, Kurnianda J,
Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R and Mok TS:
Epidermal growth factor receptor mutation analysis in previously
unanalyzed histology samples and cytology samples from the phase
III Iressa Pan-ASia Study (IPASS). Lung Cancer. 83:174–181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: West Japan Oncology Group: Gefitinib versus cisplatin plus
docetaxel in patients with non-small-cell lung cancer harbouring
mutations of the epidermal growth factor receptor (WJTOG3405): An
open label, randomised phase 3 trial. Lancet Oncol. 11:121–128.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: North-East Japan Study Group: Gefitinib or chemotherapy for
non-small-cell lung cancer with mutated EGFR. N Engl J Med.
362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Guetz GD, Landre T, Uzzan B, Chouahnia K,
Nicolas P and Morere JF: Is there a survival benefit of first-line
epidermal growth factor receptor tyrosine-kinase inhibitor
monotherapy versus chemotherapy in patients with advanced
non-small-cell lung cancer?: A meta-analysis. Target Oncol.
11:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiong S, Zheng Y, Jiang P, Liu R, Liu X,
Qian J, Gu J, Chang L, Ge D and Chu Y: PA28gamma emerges as a novel
functional target of tumour suppressor microRNA-7 in non-small-cell
lung cancer. Br J Cancer. 110:353–362. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Y, Liao Z, Chen C, Qin N, Zheng J, Tian
D, Li Y, Zhu S, Luo J and Xu L: Over-expressed microRNA-7 inhibits
the growth of human lung cancer cells via suppressing CGGBP1
expression. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 30:125–130.
2014.(In Chinese). PubMed/NCBI
|
|
17
|
Zhang Z and Zhang R: Proteasome activator
PA28 gamma regulates p53 by enhancing its MDM2-mediated
degradation. EMBO J. 27:852–864. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G,
Luo J and Ren T: MicroRNA-7-regulated TLR9 signaling-enhanced
growth and metastatic potential of human lung cancer cells by
altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt
pathway. Mol Biol Cell. 24:42–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rai K, Takigawa N, Ito S, Kashihara H,
Ichihara E, Yasuda T, Shimizu K, Tanimoto M and Kiura K: Liposomal
delivery of MicroRNA-7-expressing plasmid overcomes epidermal
growth factor receptor tyrosine kinase inhibitor-resistance in lung
cancer cells. Mol Cancer Ther. 10:1720–1727. 2011. View Article : Google Scholar : PubMed/NCBI
|
